Vivos Therapeutics, Inc.

Health Care
Medical/Dental Instruments
www.vivos.com

Moat Score

Market Cap $13.37M
PE -1
Debt -
Cash $2.34M
EV -
FCF -$14.51M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$11.24M
EBIT	-$11.24M
ROE	-255%
ROA	-100%
FCF	-$14.51M
Equity	$4.41M
Growth Stability	1
PE	-1.19
PB	3.03
P/FCF	-0.92
P/S	0.91
Price/Cash	0.18
Net Margins	-128%
Gross Margins	59%
Op. Margins	-77%
Sales Growth YoY	-12%
Sales Growth QoQ	-18%
Sales CAGR	-1%
Equity CAGR	-49%
Earnings Growth YoY	3%

Earnings Growth QoQ	37%
Sales CAGR 5Y	-1%
Equity CAGR 5Y	-49%
Earnings CAGR 3Y	-6%
Sales CAGR 3Y	-6%
Equity CAGR 3Y	-18%
Market Cap	$13.37M
Revenue	$14.63M
Assets	$11.28M
Cash	$2.34M
Shares Outstanding	5.89M
Moat Score	0%
Working Capital	-1.09M
Current Ratio	0.77
Gross Profit	$8.59M
Shares Growth 3y	24%
Equity Growth QoQ	-45%
Equity Growth YoY	657%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have been used to treat over 15,000 patients worldwide by more than 1,100 trained dentists.

SEC Filings

Direct access to Vivos Therapeutics, Inc. (VVOS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Vivos Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Vivos Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Vivos Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Vivos Therapeutics, Inc..

Years

Calculation mode

= -$145M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$15M	-$15M	-$15M	-$15M	-$15M	-$15M	-$15M	-$15M	-$15M	-$15M	-$15M	-$145M
DCF		-$13M	-$12M	-$11M	-$9.9M	-$9M	-$8.2M	-$7.4M	-$6.8M	-$6.2M	-$5.6M	-$56M
Value	-$145M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-103%	-138%	-120%	-149%	-98%	-74%	-128%
ROA	-	-48%	-60%	-174%	-127%	-73%	-100%
ROE	-	-106%	-79%	-497%	-3K%	-140%	-255%

Bad Net Margins (-128.12%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-0.37	-0.14	-	-0.09	-0.09	-
Debt over Equity	-2.52	0.13	0.1	-	2.92	0.15	-
Growth Stability	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	15%	29%	-5%	-14%	9%	-1%
Earnings YoY growth	-	53%	13%	18%	-43%	-18%	-
Equity YoY growth	-	-675%	51%	-81%	-91%	2K%	-49%
FCF YoY growth	-	5%	213%	13%	-38%	4%	-